Covington Larsen (pimplegirl1)

Qualitative and quantitative data, when purposefully integrated, unlock insights exceeding the sum of their independent contributions. The integration of diverse perspectives, a cornerstone of mixed methods research, is deeply rooted in pragmatic philosophy. Integration in research is fostered by the thoughtful consideration and application of study components including distinct mixed methods research questions, sampling strategies, data transformations, joint data displays, and integrated narrative discussions. The current manuscript investigates the significance of integration in mixed-methods research, providing real-world examples from pharmacy research, and suggesting practical strategies for its effective implementation. Epithelial ovarian cancer (EOC), often manifesting as a late-stage, widespread microscopic peritoneal disease, frequently lacks noticeable symptoms and typically presents a condition that is considered surgically incurable. Small-volume disease, and even individual cells, respond favorably to targeted therapy using the 225Ac radionuclide (with a 992-day half-life), a high-linear-energy-transfer treatment method. Using a mouse model of human EOC SKOV3 xenografts developing peritoneal carcinomatosis (PC), we investigated the therapeutic impact of 225Ac-pretargeted radioimmunotherapy (PRIT) targeting human epidermal growth factor receptor 2 (HER2). Day zero marked the intraperitoneal introduction of 105 SKOV3 cells, modified with a luciferase reporter gene, into nude mice; the resulting tumor engraftment was confirmed via bioluminescent imaging (BLI). Treatment with 1 or 2 cycles of 3-step anti-HER2 225Ac-PRIT (37 kBq/cycle as 225Ac-Proteus DOTA), separated by a 1-week interval, commenced on day 15. Over a period of 154 days, efficacy and toxicity were measured. Untreated PC-tumor-bearing nude mice exhibited a median survival of 112 days. Employing two independent response measures, we assessed the efficacy of the 225Ac-PRIT. A larger proportion of treated mice (9 mice receiving a single treatment cycle and 8 receiving two cycles; 17 mice in total, or 85%) exhibited enduring survival compared with the control mice (9 out of 27; 33%). The survival benefit was statistically significant (log-rank [Mantel-Cox] test, P = 0.00042), clearly demonstrating a prolonged survival time. A second analysis, using BLI, highlighted a noticeable difference in the integrated BLI signal area (reaching 98 d) between the control group and the treated groups, with statistical significance (P = 0.00354). Following necropsy of 8 mice in the 2-cycle treatment group (receiving a total of 74 kBq), kidney radiotoxicity was assessed as mild and did not manifest clinically (serum blood urea nitrogen and creatinine levels were within normal ranges). Dosimetry estimates for tumors and kidneys, based on a relative biological effectiveness of 5 and per 37 kBq administered, were 569 Gy and 161 Gy, respectively. One-cycle and two-cycle treatments performed with equal therapeutic success. Mild tubular changes indicative of -toxicity were observed in both therapeutic arms, as confirmed by immunohistology. Following treatment with anti-HER2 225Ac-PRIT, mice bearing EOC PC-tumors displayed histologic cures and notably prolonged survival with minimal toxicity. A potential treatment for previously incurable epithelial ovarian cancer (EOC) is targeted therapy using the 225Ac-PRIT anti-HER2 system. 177Lu-prostate-specific membrane antigen (PSMA) proves to be an effective treatment option for patients with metastatic castration-resistant prostate cancer. Treatment-related side effects that occur less frequently have not been reported to date. Detailed case studies of two men, whose treatment with 177Lu-PSMA-I&T produced a notable hypocalcemic osteosclerotic response, are presented. The clinical dataset of 177Lu-PSMA-I&T therapy patients was examined to estimate the occurrence rate and clinical link to hypocalcemia. Of th